A large meningococcal meningitis epidemic in Burkina Faso cost the health system an estimated US$7.1 million, representing nearly 2% of the country’s entire annual health budget.
In this study of a 2007 outbreak, 86% of the health system cost covered a reactive vaccination campaign using older polysaccharide vaccines. Routine vaccination with new, conjugate vaccines are expected to prevent or limit future outbreaks and thus reduce these costs.
Full Citation:
Colombini A, Badolo O, Gessner BD et al.. 2011. Cost and impact of meningitis epidemics for the public health system in Burkina Faso. Vaccine. 29.
Title of Article: Cost and impact of meningitis epidemics for the public health system in Burkina Faso
Author(s): Colombini A, Badolo O, Gessner BD et al.
Publication Year: 2011
Publication Name: Vaccine
Publication Volume: 29
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/21641952/
DOI (Digital Object Identifier): 10.1016/j.vaccine.2011.05.058
Topics: Economics & Return on Investment
Disease Vaccines: Meningitis | Meningococcal disease / MenACWY
Immunization Terms: Economic impacts
Countries: Algeria | Burkina Faso
WHO Regions: Africa